Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

rTMS for fibromyalgia: protocol departures and interpretive issues

  • Luke Parkitny, Postdoctoral Research Fellow, Stanford University, Department of Anesthesialukeparkitny@interleuk.in
  • Luke Parkitny, Palo Alto, CA; Neil Edward O'Connell, London, UK.
Submitted June 27, 2014

The Boyer et al. paper [1] diverges, without disclosure, from the registered protocol for this trial. Throughout the paper, the authors stated that quality of life (QOL) was the a priori established primary outcome measure and outlined a case for that decision. This appears as a departure from the www.clinicaltrials.gov register record (NCT00697398) that identifies analgesic efficiency as primary outcome and QOL as secondary outcome. Were the original hypotheses about pain and QOL retained, necessary corrections for multiple testing would likely obviate the significant findings presented in the paper.

The effect on QOL was small and imprecise; not reflected in concomitant change on a different QOL scale or in improvement across any outcomes that might underpin such improvement in QOL. The improvement observed at 11 weeks was not apparent after the initial 2 weeks of intensive stimulation. It is possible that the improvement in QOL was not related to the rTMS treatment. A substantially more conservative interpretation is warranted for a possibly negative trial of rTMS for fibromyalgia.

1.Boyer L, Dousset A, Roussel P, et al. rTMS in fibromyalgia A randomized trial evaluating QoL and its brain metabolic substrate. Neurology 2014; 82: 1231-1238.

For disclosures, please contact the editorial office at journal@neurology.org.

Navigate back to article

Neurology: 98 (24)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise